Back

Efficacy and limitations of quinidine therapy in patients with Brugada Syndrome

3 September 2019 (16:58 - 17:15)
Organised by:
Congress Presentation Part of: Anti-arrhythmic drug therapy: new concepts on old drugs Antiarrhythmic Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Associate Professor Andrea Mazzanti

University of Pavia, Pavia (Italy)

3 More presentations in this session

Presentation thumbnail
State of the Art from history to future of anti-arrhythmic drugs
Professor J. Camm (London, GB)
Slides Video
Presentation thumbnail
A prospective, multicenter, nationwide, observational study of flecainide controlled release on the quality of life of patients with atrial fibrillation in Greece, the REFLEC-CR study
Doctor S. Tzeis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Amiodarone in contemporary clinical practice: the rates of and reasons for permanent drug discontinuation
Doctor M. Mihajlovic (Belgrade, RS)
Abstract Slides Video

Access the full session

Session thumbnail
Anti-arrhythmic drug therapy: new concepts on old drugs

The Event

Event poster

ESC Congress 2019

3 September 2019 16:58 CET
You may be interested in
thumbnail
Congress Presentation
Why, when, and for whom should we use quinidine?
thumbnail
Congress Presentation
Monitoring the electrophysiological effects of hydroquinidine non-invasively in patients with Brugada syndrome
thumbnail
Congress Presentation
Treating the unknown: the use of anti-arrhtyhmic drugs in idiopathic ventricular fibrillation

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources